Palisade Bio Grants Equity to New Employee Under Nasdaq Rules
Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company on a mission to transform the therapeutic landscape for individuals suffering from autoimmune, inflammatory, and fibrotic diseases. Recently, the company made headlines with the announcement of an equity grant to a newly appointed employee under its 2021 Inducement Plan.
Details of the Equity Grant
This significant move highlights Palisade's dedication to attracting top talent. The company authorized the issuance of options enabling the new employee to purchase 2,600 shares of its common stock. This issuance serves as a material inducement to foster employment, complying with the guidelines outlined in Nasdaq Listing Rule 5635(c)(4).
Understanding the Option Grant
The options were granted on January 3, 2025, at an exercise price that aligns with the closing stock price on the grant date. This strategic decision reaffirms the company's commitment to its workforce and the potential for rewarding employee contributions through stock ownership.
Vesting and Employment Impact
Notably, the options will vest in equal quarterly installments over a three-year period, subject to the employee fulfilling their service obligations. This structure supports retention and promotes a long-term investment in the company’s vision and growth.
Palisade Bio's Focus on Novel Therapeutics
Palisade Bio continues to press forward in its pursuit of innovative solutions for patients affected by a range of challenging health conditions. By focusing on advancing novel therapeutics, the company aims to address gaps in treatment and improve the quality of life for individuals facing autoimmune and fibrotic diseases.
The Company’s Vision
The company firmly believes that employing a targeted approach with its unique therapeutics can revolutionize treatment modalities in the healthcare industry. With a clear commitment to research and development, Palisade Bio is working tirelessly to bring new treatments to those in need.
Further Company Information
Palisade Bio’s approach not only leverages cutting-edge biopharmaceutical technology but also emphasizes the importance of solid employee engagement and satisfaction. The establishment of a robust incentive plan, such as the recent equity grant, ensures that team members have a vested interest in the company’s success.
If you are interested in learning more about Palisade Bio and its innovative projects, you can visit their official website for detailed information and updates on their ongoing projects and initiatives.
Investor Relations Contact
For inquiries regarding investor relations, interested parties can reach out to the JTC Team, LLC. Jenene Thomas can be contacted at 908-824-0775. You may also direct your emails to PALI@jtcir.com.
Frequently Asked Questions
What is the recent announcement by Palisade Bio?
Palisade Bio announced an equity grant to a new employee under its 2021 Inducement Plan in line with Nasdaq's regulations.
How many options were granted to the new employee?
The company granted 2,600 options to purchase shares of its common stock to the new employee.
What is the vesting schedule for the options?
The options will vest quarterly over three years, contingent upon the employee's continued service.
What is Palisade Bio focused on?
Palisade Bio focuses on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases.
How can investors contact Palisade Bio?
Investors can reach out to Jenene Thomas at 908-824-0775 or via email at PALI@jtcir.com.
